EGFR and colorectal carcinoma: The antiproliferative activity of OC against CRC cells was compared with diverse anticancer drugs, including the microtubule depolymerization disruptor paclitaxel (PTX), doxorubicin (DOX), a DNA base pair intercalator and topoisomerase II inhibitor, osimertinib, a third-generation EGFR inhibitor, 5-fluorouracil (5-FU), a DNA double-strand disruptor and a standard chemotherapy for CRC, SU112274, a class I competitive inhibitor of c-MET kinase domain, and gefitinib, a first-generation EGFR inhibitor (Table 1).